EuBiologics announced Friday that its proprietary adjuvant platform EcML has completed Type IV Drug Master File registration ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results